Regeneron Pharmaceuticals Inc
REGN
$796.34+2.31%
End of day · as of Oct 15, 2026, 5:17 PM ET
Mkt cap
$59.10B
EV/Sales
4.04
P/E ratio
19.7
FY2025 Revenue
$14.34B
EPS (TTM)
$40.41
Gross Margin (FY2025)
N/A
Profit Margin (FY2025)
31.41%
Beta
0.31
Div yield
0.67%
Sector
Healthcare
No recent filings in cache.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 19.7.
Use this REGN research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full REGN income, balance, and cash tables.
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company in the Healthcare sector.
Latest cached Regeneron Pharmaceuticals Inc (REGN) revenue for Dec 31, 2025 was $14.34B. Net income was $4.50B. Statements: https://lician.com/financials/regn
Regeneron Pharmaceuticals Inc (REGN) trailing P/E is 19.7 on the latest cached fundamentals snapshot.
Regeneron Pharmaceuticals Inc (REGN) market capitalization is $59.10B on the latest cached snapshot.
Regeneron Pharmaceuticals Inc (REGN) cached previous close $778.36; day range $796.34 – $802.33; volume 798,814. Session quote: https://lician.com/quote/regn
Regeneron Pharmaceuticals Inc (REGN) latest cached earnings event is "REGN earnings" on Aug 7, 2026. Earnings calendar: https://lician.com/earnings